Drug Patents owned by Ucb Inc
1. Drug name - BRIVIACT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(3 years from now) | |
| CN1740151A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Sep, 2007
(15 years ago) | |
| CN1740150A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Oct, 2007
(14 years ago) | |
| CN1303066C | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Jul, 2010
(12 years ago) | |
| CN1680314A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Jul, 2010
(12 years ago) | |
| CN1404470A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Apr, 2015
(7 years ago) | |
| CN1179944C | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Apr, 2015
(7 years ago) | |
| CN1404469A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Feb, 2021
(1 year, 7 months ago) | |
| CN1208319C | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Feb, 2021
(1 year, 7 months ago) | |
| IN200500340P3 | UCB INC | Compound Of General Formula (A) |
Feb, 2021
(1 year, 7 months ago) | |
| IN200201000P3 | UCB INC | A 2-Oxo-1-Pyrrolidine Compound Or Pharmaceutical Salts Thereof |
Feb, 2021
(1 year, 7 months ago) | |
| IN196025B | UCB INC | [2-Oxo-1-Pyrrolidine Derivatives] Process For Preparing |
Feb, 2021
(1 year, 7 months ago) | |
| IN200075B | UCB INC | A 2- Oxo-1-Pyrrolidine Compound Or Pharmaceutical Salts |
Feb, 2021
(1 year, 7 months ago) | |
| IN234848B | UCB INC | Compound Of General Formula (A) |
Feb, 2021
(1 year, 7 months ago) | |
| EP1447399B9 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1447399B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1447399A1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1477478A2 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses. |
Feb, 2021
(1 year, 7 months ago) | |
| EP1477478A3 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses. |
Feb, 2021
(1 year, 7 months ago) | |
| EP1265862A2 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1263727A1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1477478B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses. |
Feb, 2021
(1 year, 7 months ago) | |
| EP1265862B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1263727B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1452524B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1452524A1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(7 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/5ML (10MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
2. Drug name - KEPPRA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(8 years from now) | |
|
US8802142
(Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(9 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 1GM | TABLET;ORAL | Prescription |
| 250MG | TABLET;ORAL | Prescription |
| 500MG | TABLET;ORAL | Prescription |
| 750MG | TABLET;ORAL | Prescription |
3. Drug name - KEPPRA XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858122 | UCB INC | Extended release formulation of levetiracetam |
Sep, 2028
(5 years from now) | |
Drugs and Companies using LEVETIRACETAM ingredient
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 500MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 750MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
4. Drug name - NAYZILAM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687495 | UCB INC | Methods and systems for the delivery of a therapeutic agent |
Jan, 2028
(5 years from now) | |
| US8809322 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(5 years from now) | |
| US8217033 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(5 years from now) | |
| US9289432 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(5 years from now) | |
Drugs and Companies using MIDAZOLAM ingredient
Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older
Dosage: SPRAY;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG/SPRAY | SPRAY;NASAL | Prescription |
5. Drug name - NEUPRO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(9 months from now) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(3 years from now) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(4 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(8 years from now) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(8 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(9 years from now) | |
Drugs and Companies using ROTIGOTINE ingredient
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; treatment of restless legs syndrome by application of claimed transdermal delivery system
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription |
| 2MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription |
| 3MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription |
| 4MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription |
| 6MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription |
| 8MG/24HR | FILM, EXTENDED RELEASE;TRANSDERMAL | Prescription |
6. Drug name - VIMPAT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(6 months ago) | |
| EP1038522A2 | UCB INC | Anticonvulsant Enantiomeric Amino Acid Derivatives |
Mar, 2017
(5 years ago) | |
| EP1038522B1 | UCB INC | Anticonvulsant Enantiomeric Amino Acid Derivatives |
Mar, 2017
(5 years ago) | |
| EP1038522A3 | UCB INC | Anticonvulsant Enantiomeric Amino Acid Derivatives |
Mar, 2017
(5 years ago) | |
| EP888289A1 | UCB INC | Anticonvulsant Enantiomeric Amino Acid Derivatives |
Mar, 2022
(6 months ago) | |
| EP888289B1 | UCB INC | Anticonvulsant Enantiomeric Amino Acid Derivatives |
Mar, 2022
(6 months ago) | |
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
| 150MG | TABLET;ORAL | Prescription |
| 200MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.